Commentary: Meta-Analyses Reporting the Prognostic Value of Androgen Receptor Splice Variant 7 in Castration-Resistant Prostate Cancer.
作者信息
Kattan Michael W, Bukowski Ronald M
机构信息
Department of Quantitative Health Sciences in the Lerner Research Institute, Cleveland Clinic, Cleveland, OH, United States.
Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, United States.
出版信息
Front Oncol. 2020 Nov 30;10:602992. doi: 10.3389/fonc.2020.602992. eCollection 2020.
Abstract
摘要
相似文献
1
Commentary: Meta-Analyses Reporting the Prognostic Value of Androgen Receptor Splice Variant 7 in Castration-Resistant Prostate Cancer.评论：关于雄激素受体剪接变异体7在去势抵抗性前列腺癌中的预后价值的荟萃分析
Front Oncol. 2020 Nov 30;10:602992. doi: 10.3389/fonc.2020.602992. eCollection 2020.
2
Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis.雄激素受体剪接变异体 7 在下一代雄激素受体信号抑制治疗去势抵抗性前列腺癌中的预后价值：系统评价和荟萃分析。
Eur Urol Focus. 2018 Jul;4(4):529-539. doi: 10.1016/j.euf.2017.01.004. Epub 2017 Jan 23.
3
Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival.Vav3增强雄激素受体剪接变体活性，对去势抵抗性前列腺癌的生长和存活至关重要。
Mol Endocrinol. 2012 Dec;26(12):1967-79. doi: 10.1210/me.2012-1165. Epub 2012 Sep 28.
4
Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.一种用于检测转移性去势抵抗性前列腺癌中雄激素受体剪接变体-7蛋白表达的新型免疫组织化学检测方法的分析验证和临床鉴定
Eur Urol. 2016 Oct;70(4):599-608. doi: 10.1016/j.eururo.2016.03.049. Epub 2016 Apr 23.
5
The cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cells.去势抵抗性前列腺癌细胞中雄激素受体剪接变体的顺式作用元件组和基因特征
J Urol. 2015 Feb;193(2):690-8. doi: 10.1016/j.juro.2014.08.043. Epub 2014 Aug 14.
6
Ratio of the expression levels of androgen receptor splice variant 7 to androgen receptor in castration refractory prostate cancer.去势抵抗性前列腺癌中雄激素受体剪接变体7与雄激素受体表达水平的比值。
Oncol Lett. 2021 Dec;22(6):831. doi: 10.3892/ol.2021.13092. Epub 2021 Oct 13.
7
Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials.探索去势抵抗性前列腺癌患者转移部位与雄激素受体剪接变体7（AR-V7）之间的关联：前瞻性临床试验的荟萃分析。
Pathol Res Pract. 2021 Jun;222:153440. doi: 10.1016/j.prp.2021.153440. Epub 2021 Apr 9.
8
Androgen receptor splice variant 7 in castration-resistant prostate cancer: Clinical considerations.去势抵抗性前列腺癌中的雄激素受体剪接变体7：临床考量
Int J Urol. 2016 Aug;23(8):646-53. doi: 10.1111/iju.13134. Epub 2016 Jun 3.
9
LSD1 inhibition attenuates androgen receptor V7 splice variant activation in castration resistant prostate cancer models.在去势抵抗性前列腺癌模型中，赖氨酸特异性去甲基化酶1（LSD1）抑制可减弱雄激素受体V7剪接变体的激活。
Cancer Cell Int. 2018 May 9;18:71. doi: 10.1186/s12935-018-0568-1. eCollection 2018.
10
Data of relative mRNA and protein abundances of androgen receptor splice variants in castration-resistant prostate cancer.去势抵抗性前列腺癌中雄激素受体剪接变体的相对mRNA和蛋白质丰度数据。
Data Brief. 2021 Jan 18;34:106774. doi: 10.1016/j.dib.2021.106774. eCollection 2021 Feb.
本文引用的文献
1
The Prognostic Value of Androgen Receptor Splice Variant 7 in Castration-Resistant Prostate Cancer Treated With Novel Hormonal Therapy or Chemotherapy: A Systematic Review and Meta-analysis.雄激素受体剪接变体7在接受新型激素疗法或化疗的去势抵抗性前列腺癌中的预后价值：一项系统评价和荟萃分析
Front Oncol. 2020 Nov 30;10:572590. doi: 10.3389/fonc.2020.572590. eCollection 2020.
2
Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.雄激素受体剪接变体7在转移性去势抵抗性前列腺癌治疗中的预后价值：一项系统评价和荟萃分析
Front Oncol. 2020 Nov 30;10:562504. doi: 10.3389/fonc.2020.562504. eCollection 2020.
3
Meta-analysis: Its strengths and limitations.荟萃分析：其优势与局限性。
Cleve Clin J Med. 2008 Jun;75(6):431-9. doi: 10.3949/ccjm.75.6.431.
4
Judging new markers by their ability to improve predictive accuracy.通过新标志物提高预测准确性的能力来评判它们。
J Natl Cancer Inst. 2003 May 7;95(9):634-5. doi: 10.1093/jnci/95.9.634.
5
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.预测激素难治性转移性前列腺癌男性患者生存率的预后模型。
J Clin Oncol. 2003 Apr 1;21(7):1232-7. doi: 10.1200/JCO.2003.06.100.
6
Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration.去势后进展性转移性前列腺癌患者总生存的列线图
J Clin Oncol. 2002 Oct 1;20(19):3972-82. doi: 10.1200/JCO.2002.11.021.
Zotero 插件